Table 3.
LRRK2-targeted treatments including LRRK2 inihibitors and antisense oligomeres under development for PD
| LRRK2 | Denali trial | ||||
|---|---|---|---|---|---|
| Compound | DNL-201 | No public data | No public data | No public data | BIIB094 |
| Sponsor | Denali | GSK | Pfizer | Genetech | Biogen |
| RCT No | NCT03710707 | NCT03976349 | |||
| Mechanism | LRRK2 inhibition | LRRK2 inhibition | LRRK2 inhibition | LRRK2 inhibition | Antisense oligomere |
| Status | Ongoing, recruiting, data expected end of 2019 | Planned | Under development | Under development | Ongoing |
| Phase | 1b | N/a | N/a | N/a | Phase 1 |
| Design | Multicenter, randomized, placebo-controlled | N/a | N/a | N/a | |
| Total N of pat | 30 | N/a | N/a | N/a | 62 |
| LRRK2-PD | N/a | N/a | N/a | ||
| Idiopathic PD | N/a | N/a | N/a | ||
| Age | 30–75 | N/a | N/a | N/a | 35–80 |
| Duration | 28 days | N/a | N/a | N/a | N.d. |
| Doses tested | Low / High | N/a | N/a | N/a | Single-and multiple-ascending-dose |